title: NPPO-7, IgG2, Cut&Tag

first: Jia

last: Li

institute: Columbia University Irving Medical Center

description: Library name: NPPO-7_IgG2_CST

data_processing:
CUT&Tag reads were trimmed using cutadapt (v3.6) and aligned to the mouse reference genome (mm10) and Drosophila (BDGP6) using BOWTIE2 (v2.4.2) with options: --very-sensitive-local --no-unal --no-mixed --no-discordant --phred33 -I 10 -X 700.
Scaling factors for spike-in normalization were determined by the ratio between the number of reads aligned to the mouse genome and Drosophila genome.
Potential PCR duplicates were removed by the markdup function of sambamba (v1.0.1).
Peak calling was performed using SEACR (v1.3) or MACS2 (v2.2.8) with IgG input as control.
The read counts of peaks across gene loci were counted by featureCounts (v1.6.1).
Genomic enrichment of CUT&Tag signal for each histone modification was analyzed by deeptools (v3.5.5) and visualized using IGV (v2.13.0).
Assembly: mm10/Drosophila S2
Supplementary files format and content: bigWig
Library strategy: Cut&Tag

source_name: Prostate

extract_protocol:
Organoids were dissociated into single cells using TrypLE, counted using a TC20 automated cell counter, and 200,000 cells/sample used for profiling. For experiments requiring normalization of input DNA, 10,000 Drosophila Schneider 2 (S2) cells (ThermoFisher Scientific R69007) were combined with 200,000 experimental cells at a ratio of 1:20. After centrifugation at 1000 rpm at RT, cell pellets were washed once with 1 ml wash buffer (20 mM HEPES (pH 7.5), 150 mM NaCl, 0.5 mM spermidine (Millipore-Sigma S2501), and cOmplete™, EDTA-free protease inhibitor cocktail (Millipore-Sigma 11873580001) in nuclease-free water). Cell pellets were resuspended with 10 µl ConA beads in 0.4 ml wash buffer and incubated for 10 minutes at RT. The tubes were then placed on a magnetic stand (New England Biolabs S1515S) to clear and remove the liquid, with pellets resuspended with 50 µl ice-cold Dig-wash buffer (wash buffer with 0.05% digitonin) and placed on ice for 10 min to lyse the cells. The samples were then transferred to an 8-strip tube (EpiCypher 10-0009). Each sample was incubated with 0.5 µg primary or IgG control antibody (Supplementary Table 6) and placed on a nutator at 4°C overnight. The next day, samples were incubated with 1 µl secondary antibody in 50 µl ice-cold Dig-wash buffer on a nutator at RT for 1 hr. After washing with Dig-Wash buffer three times, beads were resuspended with 50 µl Dig-300 buffer (20 mM HEPES (pH 7.5), 300 mM NaCl, 0.5 mM Spermidine, 0.01% Digitonin, cOmplete™, EDTA-free Protease Inhibitor Cocktail in nuclease-free water) containing 2.5 µl pA-Tn5 adapter complex (EpiCypher 15-1017) and placed on a nutator at RT for 1 hour. After washing three times with Dig-300 buffer, the beads were resuspended in 150 µl Tagmentation buffer (Dig-300 buffer with 10 mM MgCl2) and incubated at 37°C for 1 hr. To stop tagmentation and solubilize DNA fragments, 5 µL 0.5 M EDTA (ThermoFisher Scientific AM9260G), 1.5 µl 10% SDS (Millipore-Sigma 71736), 1.25 µl 20 mg/ml Proteinase K (ThermoFisher Scientific EO0491) was added to each sample and incubated at 37°C overnight. The next day, phenol:chloroform:isoamyl alcohol (25:24:1, v/v; ThermoFisher Scientific 15593049) was used to extract nucleic acids. DNA was precipitated with 100% ethanol (Millipore-Sigma E7023) and dissolved in 25 μl RNase-free water. To remove RNA contamination prior to library preparation, DNA samples were incubated with 25 µg/ml RNase A (ThermoFisher Scientific EN0531) at 37°C for 10 min.
Library DNAs were amplified by PCR using Illumina universal i5 primers, Nextera barcoded i7 primers, and NEBNext HiFi 2x PCR Master mix (New England Biolabs M0541). The PCR conditions were: cycle 1: 72°C for 5 min; cycle 2: 98°C for 30 sec; cycle 3: 98°C for 10 sec; cycle 4: 63°C for 10 sec, repeating 14 times, followed by 72°C for 1 min and hold at 8°C. Post-PCR clean-up was performed using 1:1 volume Ampure XP beads (Beckman Coulter A63880). Samples were dissolved in 10 mM Tris-HCl (pH 8; Millipore-Sigma T2694) for sequencing. Size distribution and concentration of libraries was determined by capillary electrophoresis using the 4200 TapeStation (Agilent). Paired-end sequencing (2x150 bp) was performed on pooled-libraries, with 10-12 million reads per library, using the Illumina HiSeq system.

value: Prostate

value: NPPO-7 organoids

value: Prostate non-NE tumor cells

tag: cut&tag antibody

value: Normal Rabbit IgG (CST, #2729)

value: No


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 4

status: Public on Dec 21 2025

type: SRA

city: Boston

first: Jonathan

middle: Andrew

last: Nowak

state: MA

address: 75 Francis St.

department: Pathology

country: USA

institute: Brigham and Women's Hospital

description:
Library name: Sample 722
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

library_source: transcriptomic

data_processing:
GeoMx DSP data were pre-processed using the GeoMxTools package (version 3.8.0) in R. DCC files containing raw count data from NGS, the PKC file pertaining to the GeoMx Human WTA, and a custom-made annotation file derived from the FASTQ lab worksheet files were condensed into an object of the GeoMxSetObject class. The GeoMxSetObject contained a total of 716 areas of illumination (AOIs) prior to quality control. AOIs were excluded from further analysis based on read metrics, sequencing saturation, and nuclei count. Probes were excluded from further analysis based on count distribution across AOIs and an outlier test and were then condensed into a gene-level count matrix. Next, all AOIs with at least 1% of genes detected and all genes detected in at least 1% of AOIs were retained in the dataset. After these quality control steps, a total of 676 AOIs remained in the dataset. Batch correction was then performed using the ComBat-Seq algorithm as implemented in the sva R package (3.52.0). Finally, count data were normalized to the third quantile and log2-transformed for downstream analysis.
AOIs were excluded from further analysis based on read metrics, sequencing saturation, and nuclei count.
Probes were excluded from further analysis based on count distribution across AOIs and an outlier test and were then condensed into a gene-level count matrix.
Next, all AOIs with at least 1% of genes detected and all genes detected in at least 1% of AOIs were retained in the dataset.
Batch correction was then performed using the ComBat-Seq algorithm as implemented in the sva R package (3.52.0).
Finally, count data were normalized to the third quantile and log2-transformed for downstream analysis.
Assembly: hg38
Supplementary files format and content: DCC files: Contains target probe counts linked to one area of illumination per file with quality control metadata.
Supplementary files format and content: PKC file: Contains information regarding the Geomx Whole Transcriptome Atlas gene panel.
Supplementary files format and content: annotation_file.xlsx: Derived from lab worksheets produced from each individual run and contains relevant metadata required for analysis as published, including de-identified patient characteristics, anatomic site of origin, and time of biopsy in relation to treatment.
Supplementary files format and content: GeoMxSetObject_postQC.RDS: Third-quartile normalized and batch-corrected data object used in all downstream analysis.
Library strategy: Spatial Transcriptomics

molecule: total RNA

organism: Homo sapiens

source_name: metastatic pancreatic adenocarcinoma

extract_protocol:
Two tumor biopsies were performed on most patients. One biopsy was performed during screening and one was performed after 4-6 weeks of treatment from the same metastatic site to acquire cores for formalin-fixed, paraffin-embedded (FFPE) blocks, frozen OCT blocks, and fresh tissue studies. Slides from FFPE tissue were hematoxylin and eosin (H&E)-stained, followed by review by a pathologist. If no viable tumor was identified in FFPE cores, OCT cores were converted to FFPE blocks if available.
The GeoMx DSP libraries were prepared according to the manufacturer's instructions for the GeoMx Human Whole Transcriptome Atlas (WTA) assay.

treatment_protocol: Each treatment cycle consisted of 28 days. All patients whose samples are represented in this study received albumin-bound paclitaxel followed by gemcitabine (GA). Albumin-bound paclitaxel was administered as a 30-minute infusion at a dose of 125 mg/m2 (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30-minute infusion for three consecutive weeks followed by a week of rest (treatment on days 1, 8, and 15, during a 28-day cycle). Patients assigned to the GA plus oral placebo arm received an oral placebo taken once daily that could not be physically distinguished from the oral paricalcitol pill. Patients assigned to the GA plus intravenous (IV) paricalcitol arm were initially scheduled to receive 25 mcg of IV paricalcitol three times weekly. However, due to clinical care restrictions imposed during the COVID pandemic, the dose was reduced to 75 mcg of IV paricalcitol weekly. Only one patient received thrice weekly dosing prior to the dosing change. Patients assigned to the GA plus PO paricalcitol arm received 16 mcg of oral paricalcitol daily, which was thought to be analogous to a cumulative weekly dose as 75 mcg of IV paricalcitol based upon the bioavailability of PO paricalcitol.

tag: tissue

value: metastatic pancreatic adenocarcinoma

tag: biopsy site

value: liver

tag: segment

tag: region of_interest_number

tag: patient id

tag: treatment

value: Gemcitabine/Nab-Paclitaxel plus Placebo

tag: biopsy timepoint

value: pre-treatment

tag: Sex

value: M

tag: race

value: White

tag: ethnicity

value: Non-Hispanic

tag: age

tag: batch


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 3

description:
Library name: Sample 718
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: Center


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 1

description:
Library name: Sample 714
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 4

description:
Library name: Sample 720
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 3

description:
Library name: Sample 719
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 1

description:
Library name: Sample 715
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 5

description:
Library name: Sample 712
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: F


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 2

description:
Library name: Sample 716
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 2

description:
Library name: Sample 717
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 1

description:
Library name: Sample 713
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 4

description:
Library name: Sample 708
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 3

description:
Library name: Sample 706
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 4

description:
Library name: Sample 709
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 5

description:
Library name: Sample 711
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 703
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 3

description:
Library name: Sample 705
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 5

description:
Library name: Sample 710
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 702
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID65, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 3

description:
Library name: Sample 699
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 701
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID65, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 3

description:
Library name: Sample 697
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 700
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID65, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 2

description:
Library name: Sample 696
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID65, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 695
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 4

description:
Library name: Sample 707
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID66, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 704
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID65, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 693
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID65, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 692
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 4

description:
Library name: Sample 721
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID65, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 3

description:
Library name: Sample 698
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID65, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 691
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 3

description:
Library name: Sample 689
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 3

description:
Library name: Sample 688
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 3

description:
Library name: Sample 690
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 686
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 684
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 685
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 683
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 2

description:
Library name: Sample 687
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID79, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 682
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: No Template Control 9

description:
Library name: Sample 681
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 4

description:
Library name: Sample 677
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: Black or African American


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 5

description:
Library name: Sample 680
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 4

description:
Library name: Sample 675
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 5

description:
Library name: Sample 678
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 5

description:
Library name: Sample 679
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 3

description:
Library name: Sample 674
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 3

description:
Library name: Sample 672
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 1

description:
Library name: Sample 669
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 2

description:
Library name: Sample 671
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 3

description:
Library name: Sample 673
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID65, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 694
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 2

description:
Library name: Sample 670
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 7

description:
Library name: Sample 665
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: on-treatment


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 7

description:
Library name: Sample 666
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 7

description:
Library name: Sample 664
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 6

description:
Library name: Sample 663
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 6

description:
Library name: Sample 662
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 5

description:
Library name: Sample 660
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 4

description:
Library name: Sample 658
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 4

description:
Library name: Sample 656
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 6

description:
Library name: Sample 661
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 3

description:
Library name: Sample 654
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 3

description:
Library name: Sample 655
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 4

description:
Library name: Sample 657
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 4

description:
Library name: Sample 676
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 1

description:
Library name: Sample 649
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 5

description:
Library name: Sample 659
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 1

description:
Library name: Sample 647
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 1

description:
Library name: Sample 648
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 2

description:
Library name: Sample 651
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 6

description:
Library name: Sample 646
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 6

description:
Library name: Sample 645
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 4

description:
Library name: Sample 640
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 5

description:
Library name: Sample 643
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 6

description:
Library name: Sample 644
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 1

description:
Library name: Sample 667
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 1

description:
Library name: Sample 668
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 4

description:
Library name: Sample 639
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 5

description:
Library name: Sample 642
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 5

description:
Library name: Sample 641
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 4

description:
Library name: Sample 638
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 2

description:
Library name: Sample 635
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 3

description:
Library name: Sample 637
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 2

description:
Library name: Sample 633
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 3

description:
Library name: Sample 636
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 1

description:
Library name: Sample 630
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 2

description:
Library name: Sample 634
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Full ROI, 4

description:
Library name: Sample 629
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: Full ROI


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 1

description:
Library name: Sample 631
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 3

description:
Library name: Sample 628
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 3

description:
Library name: Sample 627
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 2

description:
Library name: Sample 652
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 3

description:
Library name: Sample 653
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 2

description:
Library name: Sample 626
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 2

description:
Library name: Sample 625
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 1

description:
Library name: Sample 624
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Center, 1

description:
Library name: Sample 623
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 7

description:
Library name: Sample 622
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 6

description:
Library name: Sample 618
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 6

description:
Library name: Sample 617
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 5

description:
Library name: Sample 616
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 5

description:
Library name: Sample 615
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 6

description:
Library name: Sample 619
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 4

description:
Library name: Sample 611
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 7

description:
Library name: Sample 621
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 5

description:
Library name: Sample 614
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 4

description:
Library name: Sample 612
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 4

description:
Library name: Sample 613
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID77, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 1

description:
Library name: Sample 632
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 3

description:
Library name: Sample 609
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 2

description:
Library name: Sample 606
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 2

description:
Library name: Sample 605
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 3

description:
Library name: Sample 608
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 3

description:
Library name: Sample 610
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID81, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 602
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: periumbilical


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 1

description:
Library name: Sample 603
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 2

description:
Library name: Sample 607
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 1

description:
Library name: Sample 604
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID81, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 601
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 5

description:
Library name: Sample 599
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: omentum


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 5

description:
Library name: Sample 600
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 4

description:
Library name: Sample 596
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 4

description:
Library name: Sample 597
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 3

description:
Library name: Sample 595
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID90, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 7

description:
Library name: Sample 620
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 3

description:
Library name: Sample 594
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 3

description:
Library name: Sample 593
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 2

description:
Library name: Sample 592
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 1

description:
Library name: Sample 588
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 2

description:
Library name: Sample 590
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 1

description:
Library name: Sample 589
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 2

description:
Library name: Sample 591
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 1

description:
Library name: Sample 587
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 7

description:
Library name: Sample 585
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 7

description:
Library name: Sample 584
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 6

description:
Library name: Sample 582
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 5

description:
Library name: Sample 577
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 5

description:
Library name: Sample 578
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 6

description:
Library name: Sample 580
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 7

description:
Library name: Sample 583
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 4

description:
Library name: Sample 575
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 4

description:
Library name: Sample 574
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 4

description:
Library name: Sample 576
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 3

description:
Library name: Sample 572
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID67, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 4

description:
Library name: Sample 598
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 3

description:
Library name: Sample 571
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 2

description:
Library name: Sample 570
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 2

description:
Library name: Sample 650
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 569
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 567
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 568
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 566
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: No Template Control 8

description:
Library name: Sample 586
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 565
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID76, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 6

description:
Library name: Sample 564
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 6

description:
Library name: Sample 581
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID76, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 5

description:
Library name: Sample 562
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 5

description:
Library name: Sample 579
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID76, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 6

description:
Library name: Sample 563
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID76, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 559
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID76, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 5

description:
Library name: Sample 560
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID76, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 556
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID76, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 558
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID76, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 557
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 6

description:
Library name: Sample 554
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 3

description:
Library name: Sample 573
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 6

description:
Library name: Sample 553
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 5

description:
Library name: Sample 550
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID76, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 555
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 5

description:
Library name: Sample 549
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 4

description:
Library name: Sample 547
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 6

description:
Library name: Sample 552
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 4

description:
Library name: Sample 548
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 3

description:
Library name: Sample 544
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 3

description:
Library name: Sample 545
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 2

description:
Library name: Sample 542
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 2

description:
Library name: Sample 540
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 4

description:
Library name: Sample 546
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 2

description:
Library name: Sample 541
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID76, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 5

description:
Library name: Sample 561
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 1

description:
Library name: Sample 539
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 6

description:
Library name: Sample 536
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 1

description:
Library name: Sample 537
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 6

description:
Library name: Sample 534
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 5

description:
Library name: Sample 533
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 6

description:
Library name: Sample 535
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 5

description:
Library name: Sample 551
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 5

description:
Library name: Sample 532
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 4

description:
Library name: Sample 530
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 4

description:
Library name: Sample 529
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 5

description:
Library name: Sample 531
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 3

description:
Library name: Sample 526
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 3

description:
Library name: Sample 525
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 522
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 523
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 2

description:
Library name: Sample 524
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 520
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID61, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 3

description:
Library name: Sample 543
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 519
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID95, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 521
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 6

description:
Library name: Sample 517
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 6

description:
Library name: Sample 516
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID93, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 5

description:
Library name: Sample 515
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.